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Abstract
Purpose Patients with locally advanced rectal cancer (LARC) may experience a clinical complete response (cCR) to neo-
adjuvant chemoradiotherapy (NACRT) and opt for non-operative management. Pathological factors that relate to NACRT 
response have been well described. Host factors associated with response, however, are poorly defined. Calcification of the 
aortoiliac (AC) vessels supplying the rectum may influence treatment response.
Methods Patients with LARC having NACRT prior to curative surgery at Glasgow Royal Infirmary (GRI) and St Mark’s 
hospital (SMH) between 2008 and 2016 were identified. AC was scored on pre-treatment CT imaging. NACRT response 
was assessed using pathologic complete response (pCR) rates, tumour regression grades (TRGs), the NeoAdjuvant Rectal 
score and T-/N-downstaging. Associations were assessed using Chi-squared, Mantel–Haenszel and Fisher’s exact tests.
Results Of 231 patients from GRI, 79 (34%) underwent NACRT for LARC. Most were male (58%), aged over 65 (51%) with 
mid- to upper rectal tumours (56%) and clinical T3/4 (95%), node-positive (77%) disease. pCR occurred in 10 patients (13%). 
Trends were noted between higher clinical T stage and poor response by Royal College of Pathologist’s TRG (p = 0.021) and 
tumour height > 5 cm and poor response by Mandard TRG (0.068). In the SMH cohort, 49 of 333 (15%) patients underwent 
NACRT; 8 (16%) developed a pCR. AC was not associated with NACRT response in either cohort.
Conclusions AC was not associated with NACRT response in this cohort. Larger contemporary cohorts are required to better 
assess host determinants of NACRT response and develop predictive models to improve patient selection.
Keywords Calcification · Physiologic · Rectal neoplasms · Neoadjuvant therapy · Chemoradiotherapy · Hypoxia
Introduction
The management of rectal cancer has evolved significantly. 
The introduction of total mesorectal excision (TME) in the 
1980s contributed to a substantial decline in local recur-
rence rates (Heald and Ryall 1986). Further improvements 
in local control have been gained through the use of radio-
therapy in combination with a radio-sensitising agent prior 
to surgery in those with locally advanced (T stage 3 or 4 
and/or node-positive) disease (Kapiteijn et al. 2001; Sauer 
et al. 2012). In 15–20% of patients, a pathologic complete 
response (pCR) occurs where no viable tumour is found on 
histological examination of the resection specimen (Maas 
et al. 2010). On this basis, the concept of non-operative 
management was described (Habr-Gama et al. 2004). Close 
observation of patients with evidence of a clinical com-
plete response (cCR) on imaging and endoscopy following 
neoadjuvant chemoradiotherapy (NACRT) is now used in 
selected cases, avoiding the morbidity of surgery while pro-
viding comparable oncologic outcomes (Maas et al. 2011; 
Renehan et al. 2016; Dattani et al. 2018). However, TME 
following NACRT remains the standard of care for patients 
with locally advanced rectal cancer (LARC) who have an 
incomplete response or who opt for operative management 
(Gollins et al. 2017).
Grading of the response to NACRT has become a 
critical component of the management of LARC. The 
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exponential rise in the use of magnetic resonance imag-
ing (MRI) for locoregional staging pre- and post-NACRT 
has led to the development of tumour regression grades 
(TRGs) based on MRI findings (Battersby et al. 2016). The 
reference standard remains the degree of tumour regres-
sion present within the histological resection specimen 
which can be graded by a variety of pathological TRGs 
(Mandard et al. 1994; Rödel et al. 2005; Ryan et al. 2005). 
Observational studies attempting to correlate pathological 
and MRI-derived TRGs have, however, shown low levels 
of agreement (Chetty et al. 2012; Sclafani et al. 2017). 
Attempts to define the genotype associated with cCR in 
patients undergoing NACRT have been made, but fac-
tors such as intra-tumoural heterogeneity as well as the 
resource implications of gene sequencing techniques have 
prevented clinical translation (Lopes-Ramos et al. 2015). 
A simple, clinically relevant method of stratifying patients 
according to likely response to NACRT therefore repre-
sents a valuable tool in the management of patients with 
LARC.
It was recognised more than 60 years ago that hypoxia 
within the tumour microenvironment was associated with 
poorer response to radiotherapy (Thomlinson and Gray 
1955). Hypoxia results from an imbalance between oxygen 
supply and demand during carcinogenesis and leads to the 
formation of abnormal tumour vasculature (Epstein et al. 
2014). Systemic factors such as anaemia are also impli-
cated in impaired oxygen delivery and reduced radiother-
apy efficacy. Several studies have confirmed anaemia to be 
a negative prognostic indicator in response to NACRT for 
rectal cancer with greater clinical downstaging (Berardi 
et al. 2006) and higher rates of pathological regression 
(Box et al. 2005; Lee et al. 2009, 2012) reported in non-
anaemic patients.
Vascular calcification of the aorta and iliac arteries has 
been associated with inferior outcomes following colo-
rectal surgery including anastomotic leak and presumed 
to relate to impaired blood flow (Komen et  al. 2011, 
Boersema et al. 2016, Eveno et al. 2016, Norooz et al. 
2016, Pochhammer et al. 2018, Shen et al. 2019). As a 
marker of cardiovascular disease, aortic calcification may 
influence the dynamics of mesenteric flow by decreas-
ing vessel pliability and reducing arterial diameter. Such 
macrovascular flow disturbance may compound the effects 
of systemic factors including anaemia and local factors 
including tumour hypoxia. It is possible that in patients 
with rectal cancer, significant aortic calcification (AC) 
may influence response to NACRT by limiting the flow of 
oxygenated blood to the tumour region. This study aimed 
to explore the relationship between host factors including 
the degree of AC present on pre-treatment imaging and 
response to NACRT in patients with LARC.
Methods
Consecutive patients from Glasgow Royal Infirmary (GRI) 
with histologically proven rectal cancer who underwent 
neoadjuvant chemoradiation for LARC between 2008 and 
2016 were identified from a prospectively maintained data-
base. Exclusion criteria included patients who received 
short-course radiotherapy (SCRT) or systemic chemother-
apy only. SCRT is used infrequently at our institution and 
is usually reserved for those with significant comorbidity 
who are deemed unfit for long-course format. To avoid 
potential selection bias and acknowledging that a very 
small number of patients received SCRT during the study 
period, these patients were excluded. LARC was defined as 
an involved circumferential margin (tumour, lymph node, 
lymphovascular and/or perineural disease ≤ 1 mm from 
the mesorectal fascia) (Loughrey et al. 2013). Referral 
for consideration of NACRT was made following formal 
discussion in the colorectal cancer multidisciplinary team 
(MDT) meeting.
All patients underwent staging following histopatho-
logic confirmation of rectal adenocarcinoma using con-
trast-enhanced CT imaging of the thorax, abdomen and 
pelvis to rule out distant metastatic disease. In patients 
with no contraindication, locoregional staging of rectal 
cancer with pelvic MRI was performed. Tumour height 
was recorded as the distance in centimetres between the 
tumour and the anal verge on radiological staging and clas-
sified as low (< 5 cm), mid (5-10 cm) and upper (> 10 cm). 
Clinical stage was evaluated using digital rectal examina-
tion, endoscopic and radiological findings prior to treat-
ment. Patients were re-staged and their imaging reviewed 
by the MDT on completion of NACRT. Rectal resection 
incorporating TME was performed using an open or lapa-
roscopic approach approximately 8 weeks following com-
pletion of NACRT.
Clinico-pathological characteristics including details 
of the chemoradiation regimen, duration and dose were 
extracted from electronic patient records. Patients received 
long-course radiation at a dose of 45 Gy in 25 fractions 
over 5  weeks as standard. This was combined with a 
radio-sensitising agent, most commonly oral capecitabine. 
Patients with a history of significant cardiovascular dis-
ease were administered bolus 5-fluorouracil in weeks 1 and 
5 of treatment in place of capecitabine.
To assess the degree of AC, a novel semi-quantitative 
visual assessment method was used. The derivation of 
this method and rationale for its use have previously been 
described (Knight et al. 2020). Briefly, calcification in two 
aortic territories was evaluated: the proximal aorta at the 
level of the SMA (proximal AC) and the distal aorta at 
the level of the aortoiliac bifurcation (distal AC). Both 
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regions were considered separately, and a score of 0 to 
4 assigned according to the number of calcified quadrants 
visible. A maximum score of 4 was possible for proxi-
mal AC. For distal AC, a score of 0 to 4 was possible for 
each of the three vessels including the distal aorta imme-
diately proximal to the bifurcation and each common iliac 
artery at their origin. These were summed to provide a 
combined distal AC score with a maximum of 12 pos-
sible. Similar to previously published work, the degree 
of calcification was grouped into categories using the 
median:  absent (score 0), minor (less than median) or 
major (greater than median) (Harbaugh et al. 2013). A 
sample of 30 scans was analysed by five observers to 
assess inter-rater reliability in the GRI cohort, and by two 
observers in the St Mark’s cohort.
Pathological data were derived from reports issued 
at the time of resection. Tumours were staged using 
the Tumour, Nodes, Metastases (TNM) classification 
(Sobin and Fleming 1997) and according to the Royal 
College of Pathologists Dataset 2014 (Loughrey et al. 
2013). Response to NACRT was determined using T- and 
N-downstaging, the degree of histopathologic tumour 
regression and the Neoadjuvant Rectal (NAR) score 
(George et al. 2015).
The reporting pathologist’s impression of response to 
preoperative therapy was recorded retrospectively using 
the tumour regression score advocated by the AJCC (Ryan 
et al. 2005). In addition, the degree of tumour regression 
was assessed retrospectively using the Mandard (Mandard 
et al. 1994) and Rödel (Rödel et al. 2005) grading systems. 
The Mandard tumour regression grade (TRG) uses a semi-
quantitative approach to classify the proportion of residual 
cancer to scar tissue in the resection specimen. Similarly, 
the Rödel TRG assesses the amount of viable tumour in 
relation to the amount of fibrosis. The features of each 
TRG are outlined in Table 1.
The Neoadjuvant Rectal (NAR) score, a surrogate end-
point developed for use in clinical trials to predict long-
term outcome following NACRT for rectal cancer (George 
et  al. 2015), was calculated for each patient using pre-
treatment data. The formula incorporates clinical T stage 
and pathologic T and N-stage to produce a score between 
0 and 100. Lower scores are suggested to indicate short-
term benefit which may relate to improved survival. The 
difference between the pre-treatment clinical and post-treat-
ment pathologic T- and N-stage were used to assess T- and 
N-downstaging.
A cohort of 333 LARC patients at St Mark’s Hospital 
and Academic Institute was identified from a prospectively 
maintained database between May 2007 and November 
2016. Of them, 49 patients underwent NARCT following 
discussion of their cases at the local colorectal cancer MDT. 
Upon completion of the NACRT they underwent a TME for 
LARC. Data on clinical and radiological staging were not 
available; therefore, pCR rates were used to assess NACRT 
response. AC was assessed by one rater (ID). A sample of 30 
scans was scored separately by two raters (KK, ID) to assess 
inter-rater reliability.
Statistical analysis
Baseline characteristics were grouped according to standard 
thresholds and summarised using descriptive statistics. The 
intraclass correlation coefficient (ICC) was used to compare 
inter-rater reliability. ICC estimates and their 95% confident 
intervals were calculated based on a mean-rating, average 
measures, 2-way mixed-effects model. An ICC less than 
0.5 was considered poor, between 0.5 and 0.75 moderate, 
Table 1  Tumour regression grades and the corresponding histopathological criteria
Tumour regression grade Score Description
Royal college of pathologists 0 No viable cancer cells (complete response)
1 Single cells or rare small groups of cancer cells (near-complete response)
2 Residual cancer with evident tumour regression, but more than single cells or rare 
small groups of cancer cells (partial response)
3 Extensive residual cancer with no evident tumour regression (poor or no response)
Mandard 1 Complete regression—absence of residual cancer and fibrosis
2 Presence of rare residual cancer
3 An increase in the number of residual cancer cells, but predominantly fibrosis
4 Residual cancer outgrowing fibrosis
5 Absence of regressive changes
Rödel Poor (0–1) No regression or dominant tumour mass with obvious fibrosis and/or vasculopathy
Intermediate (2–3) Dominant fibrotic change with few tumour cells or groups (easy to find) or very 
few tumour cells in fibrotic tissue with or without mucous substance
Complete (4) No tumour cells, only fibrotic mass (total regression or response)
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0.75–0.9 good and greater than 0.9 excellent. Associations 
between clinico-pathological characteristics and response to 
NACRT were assessed using Chi-squared test for associa-
tion, Mantel–Haenszel or Fisher’s exact test where appropri-
ate. Statistical analysis was performed using SPSS software 
(version 26, IBM, Armonk, NY). Ethical approval for the 
study was provided by the West of Scotland Research Ethics 
Committee (17-WS-0200). The need for patient consent was 
waived due to the retrospective nature of the study.
Results
Between 2008 and 2016, 231 patients underwent rectal 
cancer resection with curative intent at Glasgow Royal 
Infirmary Fig. 1. Of these, 86 patients were considered to 
have LARC on baseline clinical, imaging and endoscopic 
evaluation and were referred for consideration of NACRT 
following MDT discussion. In total, 79 patients proceeded 
to NACRT. Exclusions included two patients who had pre-
viously undergone pelvic radiotherapy for testicular and 
prostate cancer respectively, two patients with missing clini-
cal records, two patients who received neoadjuvant systemic 
chemotherapy alone and one patient who underwent short-
course radiotherapy.
The baseline characteristics of patients in the GRI cohort 
are displayed in Table 2. The majority of patients were male 
(n = 46, 58%), aged over 65 years (n = 40, 51%) and had a 
history of smoking (n = 44, 56%). Most patients had cT stage 
3 or greater tumours (n = 75, 95%) in the mid- and upper rec-
tum (n = 44, 56%) and node-positive disease (n = 60, 76%).
The NACRT regimen consisted of long-course radio-
therapy (25 fractions of 45 Gy delivered over 5 weeks) in 
combination with oral capecitabine in 66 patients (84%). In 
13 patients (16%), 5-fluorouracil (5-FU) was administered 
during weeks 1–5 of radiotherapy; 3 patients received con-
current folinic acid. NACRT was associated with toxicities 
in 23 patients (29%), with dose reductions or treatment inter-
ruptions occurring in 8 patients (10%).
MRI following NACRT was carried out in 21 patients 
(27%). All patients proceeded to surgery following NACRT. 
Surgical resection was performed by abdominoperineal 
Abbreviations: LCRT long-course radiotherapy; NACRT neoadjuvant chemoradiotherapy; RT 
radiotherapy; SCRT short-course radiotherapy.
231 patients with rectal cancer
86 patients referred for NACRT
79 patients proceeded to LCRT
No RT (previous pelvic RT): 2 patients
Missing clinical record: 2 patients
SCRT: 1 patient
Systemic chemotherapy (liver metastases 
on pre-treatment scan): 1 patient
Systemic chemotherapy alone (proximal 








Fig. 1  Flow diagram of patients from GRI undergoing treatment for rectal cancer between 2008 and 2016
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resection in 40 patients (51%), anterior resection in 35 
patients (44%) and Hartmann’s procedure in 4 patients (5%). 
All but one patient who underwent anterior resection had a 
primary anastomosis.
A pCR was reported in 10 patients (13%). The majority 
of patients who had a pCR had low rectal tumours (60%). 
In those with an incomplete response, T-downstaging 
occurred in 26 patients (38%) and N-downstaging in 34 
patients (49%). Response to NACRT graded by the RCP 
TRG was complete in 10 patients (13%), near complete in 
16 patients (20%), partial in 31 patients (39%) and poor in 
22 (28%). Response to NACRT graded by the Mandard 
TRG was reported as complete in 11 patients (14%), rare 
residual cancer in 14 patients (18%), predominantly fibrosis 
in 13 patients (17%), residual cancer outgrowing fibrosis in 
21 patients (26%) and absence of regression in 20 patients 
(25%). Response to NACRT graded by the Rödel TRG was 
complete in 10 patients (13%), intermediate in 40 (51%) 
and poor in 29 (37%). The NAR score was less than 8 in 12 
patients (15%), 8 to 16 in 43 patients (54%) and greater than 
16 in 24 patients (30%).
Associations between baseline characteristics including 
age, gender, pre-treatment haemoglobin level, cT stage, cN 
stage, tumour height and response to NACRT are displayed 
in Tables 3, 4, 5 and 6. No associations between pre-treat-
ment host or tumour characteristics and pCR were evident. A 
statistically significant association was noted between lower 
cT stage tumours and complete or intermediate response to 
NACRT using the RCP TRG (p = 0.021). A non-significant 
trend between tumour height < 5 cm and complete response 
as graded by the Mandard TRG was noted. Expected asso-
ciations between higher cT stage and degree of T-down-
staging and nodal positivity and degree of N-downstaging 
were noted. No further statistically significant associations 
between baseline characteristics and response to NACRT 
using the Mandard TRG, Rödel TRG or T-downstaging were 
evident. A higher NAR score was associated with higher 
cN stage (p = 0.002) and tumour height < 5 cm (p = 0.002).  
The associations between the degree of AC and response 
to NACRT are shown in Table 7. Proximal AC was absent in 
45 patients (57%), minor in 19 patients (24%) and major in 
15 patients (19%) while distal AC was absent in 25 patients 
(32%), minor in 23 patients (29%) and major in 31 patients 
(39%). There were no statistically significant associations 
between the degree of proximal or distal AC and response 
to NACRT as measured by pCR rates, RCP, Mandard and 
Rödel TRGs, T-downstaging, N-downstaging or NAR 
score. The ICC for inter-rater reliability for proximal AC 
Table 2  Baseline demographics of patients undergoing neoadjuvant 
chemoradiation (n = 79)
ASA American Society of Anaesthesiology, BMI body mass index, 
cT/N clinical tumour/node stage, NACRT neoadjuvant chemoradio-
therapy
a Missing cases 1
Variable n (%)
Age  < 65 39 (49)
65–75 33 (42)
 > 75 7 (9)
Gender Female 33 (42)
Male 46 (58)




BMIa  < 30 65 (82)
 > 30 13 (17)
Smoking history No 35 (44)
Yes 44 (56)
Tumour height (distance from anal 
verge, cm)
 < 5 35 (44)
5–10 26 (33)
 > 10 18 (23)
cT stage 2 4 (5)
3 61 (77)
4 14 (18)
cN  stagea 0 18 (23)
1 23 (29)
2 37 (47)
Table 3  Associations between baseline clinico-pathological charac-
teristics and response to NACRT by histopathological response
cT/N clinical tumour/node stage, NACRT neoadjuvant chemoradio-
therapy
a Normal range 130–180 g/L for males, 110–165 g/L for females








Age (years)  < 65 36 (92) 3 (8) 0.608
65–75 26 (79) 7 (21)
 > 75 7 (100) 0 (0)
Gender Female 29 (88) 4 (12) 0.592
Male 40 (87) 6 (13)
Pre-NACRT hae-
moglobin (g/L)a
Normal 59 (86) 10 (14) 0.236
Low 10 (100) 0 (0)
cT stage 2–3 55 (84) 10 (16) 0.124
4 14 (100) 0 (0)
cN  stageb 0 14 (78) 4 (22) 0.167
1–2 54 (90) 6 (10)
Tumour height (cm)  < 5 29 (83) 6 (17) 0.226
5–10 23 (88) 3 (12)
 > 10 17 (94) 1 (6)
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was 0.89 (95% CI 0.82–0.94) and for distal AC 0.92 (95% 
CI 0.87–0.96).
Between 2007 and 2016, 333 patients with available CT 
imaging underwent rectal cancer resection with curative 
intent at St Mark’s Hospital Fig. 2. Of these, 49 patients pro-
ceeded to NACRT. The baseline characteristics of patients in 
the study cohort are displayed in Supplementary Table 1a. 
The majority of patients were male (n = 37, 75%), aged less 
than 65 years (n = 29, 59%) and were ASA grade 1 or 2 
(n = 43, 87%). A pCR occurred in 8 patients (16%).
Proximal AC was absent in 36 patients (74%), minor in 6 
patients (12%) and major in 7 patients (14%) while distal AC 
was absent in 20 patients (41%), minor in 15 patients (31%) 
and major in 14 patients (28%). For inter-rater reliability, the 
ICC for proximal AC was 0.92 (95% CI 0.84–0.96) and for 
distal AC was 0.88 (95% CI 0.75–0.94).
Table 5  Associations between 
baseline clinico-pathological 
characteristics and response 
to NACRT by T- and 
N-downstaging
cT/N clinical tumour/node stage, NACRT neoadjuvant chemoradiotherapy
a Normal range 130–180 g/L for males, 110–165 g/L for females
b Nodal stage data missing for 1 patient
T-downstaging p value N-downstaging p value
No n = 43 Yes n = 36 No n = 39 Yes n = 39
Age (years)  < 65 22 (56) 17 (44) 0.623 21 (54) 18 (46) 0.569
65–75 15 (46) 18 (54) 13 (41) 19 (59)
 > 75 6 (86) 1 (14) 5 (71) 2 (28)
Gender Female 20 (61) 13 (39) 0.351 20 (61) 13 (39) 0.109
Male 23 (50) 23 (50) 19 (42) 26 (58)
Pre-NACRT  haemoglobina Normal 39 (56) 30 (44) 0.327 33 (49) 35 (51) 0.598
Low 4 (40) 6 (60) 5 (50) 5 (50)
cT stage 2–3 39 (60) 26 (40) 0.032 29 (45) 36 (55) 0.134
4 4 (29) 10 (71) 9 (69) 4 (31)
cN  stageb 0 8 (44) 10 (56) 0.299 18 (100) 0 (0)  < 0.001
1–2 35 (58) 25 (42) 21 (35) 39 (65)
Tumour height (cm)  < 5 15 (43) 20 (57) 0.136 20 (59) 14 (41) 0.395
5–10 17 (65) 9 (35) 9 (35) 17 (65)
 > 10 11 (61) 7 (39) 9 (50) 9 (50)
Table 6  Associations between 
baseline clinico-pathological 
characteristics and response to 
NACRT by Neoadjuvant Rectal 
(NAR) score
cT/N clinical tumour/node stage, NACRT neoadjuvant chemoradiotherapy
a Normal range 130–180 g/L for males, 110–165 g/L for females
b Nodal stage data missing for 1 patient
NAR score p value
 < 8 n = 12 8–16 n = 43  > 16 n = 24
Age (years)  < 65 3 (8) 25 (25) 11 (28) 0.765
65–75 8 (24) 15 (46) 10 (30)
 > 75 1 (14) 3 (43) 3 (43)
Gender Female 5 (15) 15 (46) 13 (39) 0.303
Male 7 (15) 28 (61) 11 (24)
Pre-NACRT haemoglobin 
(g/L)a
Normal 12 (17) 35 (51) 22 (32) 0.806
Low 0 (0) 8 (80) 2 (20)
cT stage 2–3 11 (17) 35 (54) 19 (29) 0.404
4 1 (7) 8 (57) 5 (36)
cN  stageb 0 6 (33) 11 (61) 1 (6) 0.002
1–2 2 (10) 31 (52) 23 (38)
Tumour height (cm)  < 5 8 (23) 23 (66) 4 (11) 0.002
5–10 3 (12) 12 (46) 11 (42)
 > 10 1 (6) 8 (44) 9 (50)
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There were no statistically significant associations 
between the development of a pCR and age, gender or the 
degree of proximal or distal AC in the St Mark’s cohort 
(Supplementary Table 1b). This remained the case when 
patients from both cohorts were pooled (Supplementary 
Table 1c).
Discussion
In this study, neither the degree of proximal or distal aor-
tic calcification was associated with response to NACRT in 
patients with margin-threatening rectal cancer. Distal AC 
was more common than proximal AC in both cohorts. When 
compared to patients with rectal cancer who did not undergo 
NACRT (data not shown), both proximal and distal calcifica-
tion rates were similar, suggesting the degree of calcification 
in this study cohort was representative of that in patients 
with rectal cancer who proceeded directly to surgery.
The absence of an association between the degree of 
calcification and NACRT response may be related to sev-
eral factors. The small number of patients with a com-
plete response (n = 10, 13% GRI, n = 8, 16% SMH) is 
likely to limit our ability to detect a relationship. This 
may also underlie the lack of association between treat-
ment response and anaemia, present in only 10 patients 
from the GRI cohort. Using the TRGs, most patients were 
categorised as having an intermediate response, making 
differentiation of factors predisposing to a complete or 
poor response difficult. However, binary response meas-
ures such as T- and N-downstaging were not associated 
with the degree of aortic calcification.
The optimal endpoint for assessment of response 
to neoadjuvant therapy is a source of ongoing debate. 
Tumour regression grades are commonly associated with 
high rates of interobserver variability (Chetty et al. 2012). 
The variable diagnostic performance of MRI (Horvat et al. 
2018) and the need for multiple integrated sequences to 
improve predictive capacity for pCR (Maas et al. 2015; 
Hötker et al. 2016) limit their use. Moreover, wide varia-
tion in pCR rates across institutions has been attributed to 
differences in the thoroughness of pathological examina-
tion (Chow et al. 2019). The NAR score was developed 
as a surrogate endpoint for use in clinical trials which 
involve assessment of response to NACRT, but its predic-
tive value has been disputed in subsequent studies (van der 
Valk et al. 2019). The use of multiple metrics of tumour 
response was therefore undertaken in this study. However, 
no association between these measures and the degree of 
aortic calcification was evident in either cohort. It was 
notable that variables such as tumour height which are 
associated with NACRT response in other series did not 
consistently show significant associations with measures 
Table 7  Comparison of response to NACRT by the degree of calcification
AC aortic calcification, NAR Neoadjuvant Rectal score, pCR pathologic complete response, TRG tumour regression grade
Proximal AC Distal AC
None n = 45 Minor n = 19 Major n = 15 p value None n = 25 Minor n = 23 Major n = 31 p value
pCR No 39 (57) 17 (25) 13 (18) 0.931 23 (33) 18 (26) 28 (41) 0.923




Complete (0) 6 (60) 2 (20) 2 (20) 0.720 2 (20) 5 (50) 3 (30) 0.652
Intermediate (1–2) 28 (60) 10 (21) 9 (19) 17 (36) 12 (26) 18 (38)
Poor (3) 11 (50) 7 (32) 4 (18) 6 (27) 6 (27) 10 (46)
TRG—Mandard Complete (1) 7 (64) 2 (18) 2 (18) 0.923 3 (27) 5 (46) 3 (27) 0.473
Intermediate (2–4) 27 (56) 11 (23) 10 (21) 16 (33) 14 (29) 18 (38)
Poor (5) 11 (55) 6 (30) 3 (15) 6 (30) 4 (20) 10 (50)
TRG—Rödel Complete (4) 6 (60) 2 (20) 2 (20) 0.793 2 (20) 5 (50) 3 (30) 0.606
Intermediate (2–3) 24 (60) 8 (20) 8 (20) 15 (38) 10 (25) 15 (38)
Poor (0–1) 15 (52) 9 (31) 5 (17) 8 (28) 8 (28) 13 (45)
T-downstaging No 22 (51) 14 (33) 7 (16) 0.704 13 (30) 12 (28) 18 (42) 0.642
Yes 23 (64) 5 (14) 8 (22) 12 (33) 11 (31) 13 (36)
N-downstaging No 22 (58) 10 (26) 6 (16) 0.592 10 (26) 13 (34) 15 (40) 0.580
Yes 22 (55) 9 (23) 9 (23) 15 (38) 9 (22) 16 (40)
NAR score Low (< 8) 6 (50) 2 (17) 4 (33) 0.924 2 (17) 5 (42) 5 (42) 0.555
Intermediate 
(8–16)
27 (63) 10 (23) 6 (14) 15 (35) 11 (26) 17 (40)
High (> 16) 12 (50) 7 (29) 5 (21) 8 (33) 7 (29) 9 (38)
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of NACRT response, suggesting an expanded sample size 
is required to validate the study findings.
Relatively few studies have examined the relationship 
between aspects of comorbidity and treatment response. 
Anderson and colleagues found hypertension to be the sole 
component of the metabolic syndrome (hypertension, obe-
sity, hypertriglyceridaemia, elevated fasting glucose and 
reduced HDL cholesterol) associated with reduced odds of 
complete response in a cohort of 102 patients with a pCR 
rate of 17% (Anderson et al. 2016). However, a limited num-
ber of patients had metabolic syndrome in this study (6%) 
while 50% had hypertension which was poorly defined in 
the study methods. Blood pressure was not measured before 
or during NACRT and it is possible that patients with a his-
tory of hypertension were normotensive on minimal medica-
tion, limiting the reliability of the findings. A further study 
examining the impact of diabetes mellitus on response to 
NACRT in 102 patients with rectal cancer reported simi-
lar rates of tumour downstaging between diabetic and 
non-diabetic patients but a difference in pCR rates (Caudle 
et al. 2008). None of the patients with diabetes were found 
to have a complete response compared with 24% of their 
non-diabetic counterparts. Although the small cohort size 
also limits generalisability, the possibility that microvascu-
lar rather than macrovascular calcification, as is common 
in diabetes, could influence radiotherapy response warrants 
further exploration.
Comparison of the tumour microenvironment charac-
teristics and the degree of calcification in the patients in 
this study would have provided clarity on the relationship 
between aortic calcification and markers of tumour hypoxia. 
However, availability of tissue for analysis from patients 
within the cohort was limited. Future studies examining 
NACRT response in relation to patient and tumour micro-
environment characteristics are required. Moreover, the pau-
city of data on the effect of comorbidity on NACRT response 
suggests integration of comorbidity indices would provide 
more context to assess the clinical relevance of aortic calci-
fication in patients with rectal cancer.
Several practical aspects must also be considered: 
the use of NACRT for LARC within the UK is variable 
(Morris et al. 2016) as demonstrated by the differences 
in the proportion of patients undergoing NACRT in the 
two cohorts described here (34% GRI, 15% St Mark’s). In 
Abbreviations: LCRT long-course radiotherapy; NACRT neoadjuvant chemoradiotherapy.
333 patients with rectal cancer
66 patients referred for NACRT
49 patients proceeded to LCRT








Fig. 2  Flow diagram of patients from St Mark’s Hospital undergoing treatment for rectal cancer between 2008 and 2016
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addition, use of NACRT in the UK is generally reserved 
for poor prognosis tumours, i.e. low margin-threatening 
node-positive tumours whereas NACRT in North America 
is not restricted to such so-called “ugly” tumours. Debate 
continues regarding the optimal format of NACRT (short-
course radiotherapy versus long-course chemoradiation) 
while trials are underway examining the addition of sys-
temic chemotherapy to the neoadjuvant treatment schedule 
(total neoadjuvant therapy) (Garcia-Aguilar et al. 2020). 
Such differences in treatment indication and format neces-
sitate examination of the influence of host factors on 
NACRT response in a large contemporary cohort. Tech-
niques such as propensity-score matching may be required 
to enable reliable comparison between cohorts from UK, 
Europe and North America.
As described, this study has several limitations. In 
addition, data on tumour volume pre- and post-NACRT 
as a response metric were limited. Similarly, only a small 
number of patients had both pre- and post-NACRT MR 
imaging available to enable MRI-based assessment of 
treatment response. The use of 5-FU in place of capecit-
abine in patients with established cardiovascular disease 
among the GRI cohort may also have influenced response 
to NACRT. The St Mark’s dataset contained a small pro-
portion of patients undergoing NACRT and was limited by 
the absence of clinical staging and MRI data, restricting 
response to treatment analysis to pCR only. However, the 
reference standard for NACRT response remains histopatho-
logical examination, suggesting additional proxy measures 
may have little impact on the study findings.
In conclusion, in the absence of an available larger cohort 
in which to examine NACRT response in relation to host 
characteristics, these data suggest that aortic calcification 
does not appear to significantly influence treatment response. 
Further work to assess the degree of hypoxia within the 
tumour microenvironment may provide additional infor-
mation on the relationship between vascular calcification, 
tumour hypoxia and NACRT response.
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